Treatment for Pulmonary Arterial Hypertension Cleared PDF Print E-mail
Thursday, 17 September 2009 14:50
taken from http://www.flickr.com/photos/dhedwards/383835919/Renal & Urology News has recently reported in its September Issue that the FDA has cleared Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH). Developed by United Therapeutics Corp., of Silver Spring, Md., treprostinil is indicated to increase walk distance in patients with New York Heart Association Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with Scleroderma and congenital heart disease.

In the TRIUMPH-1 randomized, double-blind, 12-week, placebo-controlled clinical trial, patients taking treprostinil in four daily inhalation sessions achieved a 20-meter improvement in six-minute walk distance compared with placebo recipients. The safety and effectiveness in patients with underlying lung disease has not been established. The most common side effects seen with treprostinil were cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, and diarrhea.
 
More articles :

» A Hands-On Approach to Improved Health

What therapy can help decrease pain, anxiety, stress and depression? It can help patients with arthritis, lymphedema, fibromyalgia, , pregnancy and psychological disorders. And it even can help relieve agitation that may occur with Alzheimer's...

» Pulmonary Arterial Hypertension: Bridging The Present To The Future

The past decade has witnessed extensive progress in basic and clinical research in the field of pulmonary hypertension (PH), a group of chronic conditions characterised by high pressure in the pulmonary circulation. National and international PH...

» Egr-1: A Target for Scleroderma Therapy

Two separate research groups funded by the (NIAMS) have discovered that the molecule EGR-1 (early growth response 1), which regulates gene expression, plays a central role in the development of fibrosis, a condition in which organ-supporting tissue...

» Moves Toward Personalized Medicine for Scleroderma

researchers have received two five-year grants totaling $953,000 from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases to study , an autoimmune disease for which there currently is no...

» Pathogenesis and Therapeutic Approaches for Improved Topical Treatment in Localized Scleroderma and Systemic Sclerosis

I. Badea; M. Taylor; A. Rosenberg; M. FoldvariPosted: 09/03/2009; Rheumatology. 2009;48(3):213-221. © 2009 Oxford University PressSSc is a chronic progressive disorder of unknown aetiology characterized by excess synthesis and deposition of...

» Women and Autoimmunity

50:1, 9:1, 2:1 these are just some ratios of autoimmune disease disparities between women and men. The Society for Women’s Health Research (SWHR) hosted the Capitol Hill briefing, The War Within: Women and Autoimmunity, on Tuesday, October 11 to...